Evidence map›Paper›PMID 29521237›Full record

ReviewCurrent neuropharmacology2019

Closed-loop Neuropharmacology for Epilepsy: Distant Dream or Future Reality?

Irene Aicua-Rapun, Pascal André, Jan Novy

Abstract readReview
In one paragraph

Review in Current neuropharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Irene Aicua-RapunDepartment of Clinical Neurosciences, University Hospital and Faculty of Biology and Medicine, Lausanne, Switzerland.
Pascal AndréDivision of Clinical Pharmacology, University Hospital and Faculty of Biology and Medicine, Lausanne, Switzerland.
Jan NovyDepartment of Clinical Neurosciences, University Hospital and Faculty of Biology and Medicine, Lausanne, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Epilepsy is considered the most frequent severe neurological condition but most patients treated with medication become seizure free. The management of treatment, however, is highly empirical, mainly relying on observation. A closed-loop therapy for epilepsy would be very valuable for more efficient treatment regimens. Here we discuss monitoring treatment (therapeutic drug monitoring) and the potential developments in this field, as well as providing a review of potential biomarkers that could be used to monitor the disease activity. Finally, we consider the pharmacogenetic input in epilepsy treatment.

Indexed as

AnticonvulsantsBiomarkersCytokinesDrug MonitoringEpilepsyHormonesHumansNeuropharmacologyPharmacogeneticsRandomized Controlled Trials as TopicAnticonvulsantsBiomarkersCytokinesHormonesBiomarkers in epilepsycytokinesgenetic factorshormonespharmacogeneticsrefractory epilepsytherapeutic drug monitoring.

Identifiers

PMID29521237
PMCPMC6520584

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.